Not much in that.
Still no idea why Novartis terminated the agreement. And a significant delay while everything is transferred back to Imugene.
They've got enough cash for at least a year, maybe two, and if they stop R&D completely three or maybe even four years.
The question is, can they find a new partner (or negotiate an outright sale of some kind) - and is the technology actually worth anything?
Definitely a high-risk gamble now, though at current market valuation possibly a reasonable one.
Ann: Annual Report to shareholders , page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.7¢ | $2.298M | 47.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1925982 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 3452098 | 12 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |